Blog des AK Psychiatriekritik der NFJ Berlin

Kategorie: Ritalin

The Federal Report on Financial Relationships Between Pharma Industry and Prescribing Physicians

But Shadows Remain on the Controversial ADHD Drug Market

The new Social Security Act, an Obamacare-inspired, Open Payments report came out September 30th. As part of the new healthcare reform policy, this federal report requires pharmaceutical and medical device companies to annually share documentation of direct payments they provided to entities such as medical practices and teaching hospitals. The goal of Open Payments is to monitor how much doctors are receiving in the form of cash payments or incentives (e.g., free meals, travel junkets, and entertainment) related to the promotion of specific drugs and medical devices marketed in the USA. Details from 2013 reveal that hundreds of pharmaceutical companies (as well as medical device companies) gave a combined $3.5 billion to doctors nationwide.


News Flash: 4.5 Million Children Forced Daily by “Caretakers” to Do Cocaine-like Drugs

Before we get to the meat and potatoes documenting how this headline is not only shocking but also accurate, you must know that a secondary goal of this blog is to test a few theories. I have been pondering these theories because it seems to be a mystery as to why (after more than two decades of whistleblowers warning the public) so many adults have not heard or heeded the news that ADHD stimulant drugs, which are not that different from cocaine, are extremely dangerous for kids.

One of the theories is to explore if shocking headlines are still effective in catching our attention, or have we grown desensitized? My other theory is that no matter what the headline, most would rather watch YouTube videos on their smart phones, tablets or computers on the subject rather than read the details. So in order to test these theories, I have created a few animated short videos that basically share the same information as this blog. Rest assured I will keep a close eye on the view counts of both this blog and the videos for the next week or so, and get back to you on the results.

But for this little informal online study to work, I’m going to need your help.


Drugging Toddlers for Inattention, Impulsivity, and Hyperactivity

On May 16, the New York Times ran an article titled Thousands of Toddlers Are Medicated for A.D.H.D., Report Finds, Raising Worriesby Alan Schwarz.  Here is the opening sentence:

“More than 10,000 American toddlers 2 or 3 years old are being medicated for attention deficit hyperactivity disorder outside established pediatric guidelines, according to data presented on Friday by an official at the Centers for Disease Control and Prevention.”

The CDC official is Susanna Visser, MS, DrPh, Acting Associate Director of Science for the Division of Human Development and Disability, and she was speaking at the annual Rosalyn Carter Georgia Mental Health Forum.  I have not been able to find the text of Ms. Visser’s speech.  (It will probably be published later.)  Meanwhile, there is a good deal of information in Alan Schwarz’s article.  Here are some more quotes:


Imaging study shows dopamine dysfunction is not the main cause of Attention Deficit Hyperactivity Disorder (ADHD)

A study funded by the Medical Research Council (MRC) and published in Brain today found that administering methylphenidate (more commonly known as Ritalin) to healthy volunteers, as well as those who exhibit symptoms of ADHD as adults, led to similar increases of the chemical dopamine in their brain. Both groups also had equivalent level of improvements caused by the drug when they then carried out tests of their ability to concentrate and pay attention.

ADHD Drugs Don’t Boost Kids‘ Grades

Studies of Children With Attention-Deficit Hyperactivity Disorder Find Little Change

It’s no longer shocking to hear of children with attention-deficit hyperactivity disorder—and others simply facing a big test—taking ADHD medicine to boost their performance in school. But new studies point to a problem: There’s little evidence that the drugs actually improve academic outcomes.